Cargando…

The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine

PURPOSE: Studies of patients with ulcerative colitis (UC) report that reduced clinical symptoms and endoscopic activity predict better health-related quality of life (HRQoL). However, no study has examined the joint and unique associations of clinical and endoscopic activity with HRQoL, nor of histo...

Descripción completa

Detalles Bibliográficos
Autores principales: Yarlas, Aaron, Willian, Mary Kaye, Nag, Arpita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233235/
https://www.ncbi.nlm.nih.gov/pubmed/33651279
http://dx.doi.org/10.1007/s11136-021-02787-4
_version_ 1783713806097055744
author Yarlas, Aaron
Willian, Mary Kaye
Nag, Arpita
author_facet Yarlas, Aaron
Willian, Mary Kaye
Nag, Arpita
author_sort Yarlas, Aaron
collection PubMed
description PURPOSE: Studies of patients with ulcerative colitis (UC) report that reduced clinical symptoms and endoscopic activity predict better health-related quality of life (HRQoL). However, no study has examined the joint and unique associations of clinical and endoscopic activity with HRQoL, nor of histologic inflammation and HRQoL. These post hoc analyses evaluated whether reduced clinical, endoscopic, and histologic disease activity were uniquely associated with improved HRQoL for adults with active mild-to-moderate UC receiving once-daily 4.8 g/day multimatrix mesalazine for 8 weeks. METHODS: Assessments at baseline and week 8 (i.e., treatment completion) included clinical and endoscopic activity (modified UC-Disease Activity Index), histology (Geboes scoring), and HRQoL (Short Inflammatory Bowel Disease Questionnaire [SIBDQ]; SF-12v2(®) Health Survey [SF-12v2]). Associations among each type of disease activity and HRQoL were examined by correlations and by mean changes in SIBDQ and SF-12v2 scores between disease activity subgroups (e.g., achievement of clinical remission; mucosal healing). Regression models estimated unique variance in HRQoL accounted by each type of disease activity. RESULTS: Within the analysis sample (n = 717), patients with reduced clinical and endoscopic activity had significantly larger improvements in all HRQoL domains (p < 0.001), as did patients in both endoscopic and clinical remission compared to patients in endoscopic remission only (p < 0.05). Patients with histologic activity post-treatment scored significantly worse on all HRQoL domains than patients with no activity (p < 0.05). Correlations and regression models found that decreases in clinical and endoscopic activity were associated with improvements in HRQoL domain scores. CONCLUSIONS: Clinical symptoms and mucosal health have separable, distinct impacts on UC patients’ HRQoL. SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s11136-021-02787-4) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-8233235
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-82332352021-07-09 The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine Yarlas, Aaron Willian, Mary Kaye Nag, Arpita Qual Life Res Article PURPOSE: Studies of patients with ulcerative colitis (UC) report that reduced clinical symptoms and endoscopic activity predict better health-related quality of life (HRQoL). However, no study has examined the joint and unique associations of clinical and endoscopic activity with HRQoL, nor of histologic inflammation and HRQoL. These post hoc analyses evaluated whether reduced clinical, endoscopic, and histologic disease activity were uniquely associated with improved HRQoL for adults with active mild-to-moderate UC receiving once-daily 4.8 g/day multimatrix mesalazine for 8 weeks. METHODS: Assessments at baseline and week 8 (i.e., treatment completion) included clinical and endoscopic activity (modified UC-Disease Activity Index), histology (Geboes scoring), and HRQoL (Short Inflammatory Bowel Disease Questionnaire [SIBDQ]; SF-12v2(®) Health Survey [SF-12v2]). Associations among each type of disease activity and HRQoL were examined by correlations and by mean changes in SIBDQ and SF-12v2 scores between disease activity subgroups (e.g., achievement of clinical remission; mucosal healing). Regression models estimated unique variance in HRQoL accounted by each type of disease activity. RESULTS: Within the analysis sample (n = 717), patients with reduced clinical and endoscopic activity had significantly larger improvements in all HRQoL domains (p < 0.001), as did patients in both endoscopic and clinical remission compared to patients in endoscopic remission only (p < 0.05). Patients with histologic activity post-treatment scored significantly worse on all HRQoL domains than patients with no activity (p < 0.05). Correlations and regression models found that decreases in clinical and endoscopic activity were associated with improvements in HRQoL domain scores. CONCLUSIONS: Clinical symptoms and mucosal health have separable, distinct impacts on UC patients’ HRQoL. SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s11136-021-02787-4) contains supplementary material, which is available to authorized users. Springer International Publishing 2021-03-02 2021 /pmc/articles/PMC8233235/ /pubmed/33651279 http://dx.doi.org/10.1007/s11136-021-02787-4 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Yarlas, Aaron
Willian, Mary Kaye
Nag, Arpita
The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine
title The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine
title_full The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine
title_fullStr The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine
title_full_unstemmed The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine
title_short The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine
title_sort impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8233235/
https://www.ncbi.nlm.nih.gov/pubmed/33651279
http://dx.doi.org/10.1007/s11136-021-02787-4
work_keys_str_mv AT yarlasaaron theimpactofclinicalsymptomsandendoscopicandhistologicdiseaseactivityonhealthrelatedqualityoflifeinpatientswithulcerativecolitisfollowingtreatmentwithmultimatrixmesalazine
AT willianmarykaye theimpactofclinicalsymptomsandendoscopicandhistologicdiseaseactivityonhealthrelatedqualityoflifeinpatientswithulcerativecolitisfollowingtreatmentwithmultimatrixmesalazine
AT nagarpita theimpactofclinicalsymptomsandendoscopicandhistologicdiseaseactivityonhealthrelatedqualityoflifeinpatientswithulcerativecolitisfollowingtreatmentwithmultimatrixmesalazine
AT yarlasaaron impactofclinicalsymptomsandendoscopicandhistologicdiseaseactivityonhealthrelatedqualityoflifeinpatientswithulcerativecolitisfollowingtreatmentwithmultimatrixmesalazine
AT willianmarykaye impactofclinicalsymptomsandendoscopicandhistologicdiseaseactivityonhealthrelatedqualityoflifeinpatientswithulcerativecolitisfollowingtreatmentwithmultimatrixmesalazine
AT nagarpita impactofclinicalsymptomsandendoscopicandhistologicdiseaseactivityonhealthrelatedqualityoflifeinpatientswithulcerativecolitisfollowingtreatmentwithmultimatrixmesalazine